SAN DIEGO - TelAve -- Sesh Incorporated, a San Diego-based precision immuno-oncology company and Connect Cool Company led by founder and CEO Andrew Sinkoe, Ph.D., has been named the winner of the 2026 SDSU San Diego Angel Conference, receiving a $200,000 investment to support the continued commercialization of its blood-based liquid biopsy technology.

The investment will help Sesh advance its mission to improve treatment outcomes for cancer patients by developing a blood test designed to help clinicians determine the right individualized treatment path for each patient. Sesh's technology focuses on using liquid biopsy testing to detect predictive cancer biomarkers from a simple blood draw, supporting more personalized and timely cancer treatment decisions.

"Winning the SDSU San Diego Angel Conference is an incredible honor for Sesh and a meaningful step forward for our work in precision oncology," said Andrew Sinkoe, founder and CEO of Sesh Incorporated. "This investment will help us continue commercializing our blood test so we can support better, more individualized treatment decisions for cancer patients. We are deeply grateful to the SDAC investors, organizers, interns, sponsors, and the broader San Diego innovation community for believing in our vision."

More on TelAve News

• netElastic Powers LigaT's High-Performance Broadband Expansion and IPv6 Modernization in Portugal
• Raiku launches rkuSOL with Sanctum, Kamino, Loopscale and Exponent
• Greenland Mines Ltd (N A S D A Q: GRML) Advances Strategic Growth Initiatives as Critical Minerals Demand Accelerates
• Entering the $69 Billion Animal Health Market, Delivering Record Growth, AI-Driven Healthcare Innovation, and Targeting $200 Million Revenue by 2029
• $97.9 Million Q1 Revenue Growth Reinforces Transformation Into a Global AI & Digital Services Powerhouse: IQSTEL, Inc. (N A S D A Q: IQST)

Sesh's momentum reflects the strength of San Diego's life sciences and startup ecosystem. The company has received support from organizations and programs including Connect, EvoNexus, the National Cancer Institute, the Brink San Diego & Imperial Small Business Development Center Network, and the SDSU San Diego Angel Conference.

The 2026 SDSU San Diego Angel Conference brought together investors, founders, students and community leaders for a competitive process designed to provide early-stage startups with investor feedback, visibility and potential funding. Sesh was selected from a competitive finalist group that included Connect Springboard company Vayim among My Village Innovations, Shezza, PolyVascular and Cytodyme.

My Village Innovations and Vayim each received $35,000 investments through the conference.

"One of the most meaningful parts of SDAC was getting to know the other finalist companies and learning about the important work they are building," Sinkoe said. "The competition was strong because the companies were strong. We are grateful for the camaraderie, the feedback and the shared commitment to building companies that can make a real difference."

More on TelAve News

• AI Is Fueling New Growth at HP, Cisco, Dell, Intel, Nokia and More: Industry Analyst Jeff Kagan
• Boston Industrial Solutions Launches Natron® 348 UV Inkjet Ink for Epson S3200 Print Heads
• Heritage at South Brunswick Unveils Luxury Resort-Style Amenities Designed for Every Generation
• CAPHRA warns push for ASEAN vape ban ignores science
• Your Mortgage Toolbox Launches Free Mortgage Calculators That Show the Real Monthly Payment and Cash Needed to Close

The SDAC fund will continue accepting additional investments in Sesh throughout June. Interested investors may contact Sinkoe or SDAC Fund Manager Neal Bloom for more information.

With the new investment, Sesh will continue advancing its precision oncology platform with the goal of helping more patients receive the therapies most likely to benefit them.

"Let's save many lives using precision oncology," Sinkoe said.

Learn more about Sesh at https://www.oncologysesh.com/.